Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL4092771

O=C(O)C(F)(F)F.O=C(O)C(F)(F)F.O=c1cc(-c2[nH]c(Cl)nc2-c2cccnc2)cc[nH]1

nearest known ligand 0.41

Full drug profile on Sugi Atlas →

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 1/20 0.41
CYP19A1 P11511 1/20 0.40
BRAF P15056 2/20 0.38
MAPK14 Q16539 3/20 0.37
MAPK13 O15264 1/20 0.37
MAPK12 P53778 1/20 0.37
MAPK11 Q15759 1/20 0.37
NOTUM Q6P988 1/20 0.36
MAPT P10636 1/20 0.35
AOC3 Q16853 2/20 0.35
KCNH2 Q12809 1/20 0.35
CDC7 O00311 1/20 0.35
DBF4 Q9UBU7 1/20 0.35
KMO O15229 1/20 0.35
KMT2A Q03164 1/20 0.35
PIKFYVE Q9Y2I7 3/20 0.35
F2 P00734 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13741481 0.90 CYP19A1 (0.44) CYP19A1BRAFMAPK14MAPK13MAPK12
Trifluoroacetic Acid SCHEMBL4091388 0.81 CDC7 (0.40) L3MBTL1CDC7DBF4
SCHEMBL13740667 0.80 NOTUM (0.54) L3MBTL1MAPK14MAPK13MAPK12MAPK11
SCHEMBL4096709 0.76 MAPK14 (0.43) CYP19A1BRAFMAPK14MAPK13MAPK12
SCHEMBL4105858 0.73 MAPK13 (0.60) BRAFMAPK14MAPK13MAPK12MAPK11
SCHEMBL4090706 0.71 ADORA2B (0.57) CYP19A1BRAFMAPK14MAPK13MAPK12
SCHEMBL13741720 0.71 CDC7 (0.44) CYP19A1MAPK14MAPTCDC7DBF4
SCHEMBL30494229 0.70 NOTUM (0.61) CYP19A1NOTUMKMOKMT2A
SCHEMBL26462950 0.70 NOTUM (0.61) CYP19A1NOTUMKMOKMT2A
SCHEMBL5762068 0.66 MAPK13 (0.68) BRAFMAPK14MAPK13MAPK12MAPK11

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION 2009-08-27 US disclosed
US-20060106020-A1 Tetracyclic inhibitors of Janus kinases INCYTE CORPORATION 2006-05-18 US disclosed
WO-2005105814-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES INCYTE CORPORATION (US) 2005-11-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090215766-A1 TETRACYCLIC INHIBITORS OF JANUS KINASES JAK1, JAK2, JAK3 L3MBTL1 2080/4885CYP19A1 4129/4885BRAF 161/4885
US-20060106020-A1 Tetracyclic inhibitors of Janus kinases JAK1, JAK2, JAK3 L3MBTL1 2080/4885CYP19A1 4129/4885BRAF 161/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.